Onyx Pharmaceuticals, Inc.

Warner-lambert Company

Sagres Discovery, Inc.

Ali Fattaey

Terry Hermiston

Leisa Johnson

Sylvie Laquerre

Diane H Boschelli

Annette Marian Doherty

Ellen Myra Dobrusin

David W Fry

Mark Robert Barvian

David W Morris

Yuqiao Shen

Christin Tse

Marc S Malandro

Albert Lai

Robert Booher

Zhipei Wu

Jerry Yuqiao Shen

Susanne Andrea Trumpp-Kallmeyer

Viral vectors and methods of making such vectors are described that preferentially kill neoplastic but not normal cells, the preferred vector being an adenovirus that has the endogenous promoters in the E1A and/or E4 regions substituted with a tumor specific promoter which is preferably E2F responsive.

Oncolytic adenovirus

The present invention relates to novel sequences for use in detection, diagnosis and treatment of cancers, especially lymphomas. The invention provides cancer-associated (CA) polynucleotide sequences whose expression is associated with cancer. The present invention provides CA polypeptides associated with cancer that are present on the cell surface and present novel therapeutic targets against cancer. The present invention further provides diagnostic compositions and methods for the detection of cancer. The present invention provides monoclonal and polyclonal antibodies specific for the CA polypeptides. The present invention also provides diagnostic tools and therapeutic compositions and methods for screening, prevention and treatment of cancer.

Therapeutic targets in cancer

Compositions of matter consisting of a family of related nucleic acid sequences that encode proteins, termed Cell Growth Regulatory Proteins, that phosphorylate cell cycle targets, and methods of using the nucleotide sequences and the proteins encoded thereby, to diagnose and/or treat disease where the Cell Growth Regulatory Proteins have an apparent molecular weight of about 54.6 kdaltons.

Nucleic acid that encode a cell growth regulatory protein

Pyrido&lsqb;2,3-D&rsqb;pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation

Methods and compositions for determining the tumor suppressor status of cells are described, preferably as pertaining to the p53 status of tumor cells, and preferably in vivo using a recombinant construct consisting of a first polynucleotide sequence that encodes a reporter molecule and a second p53 binding polynucleotide sequence that is operably linked to the first polynucleotide sequence such that binding of p53 to the second polynucleotide sequence causes the expression of the reporter molecule which can be detected or quantified.

Plasmids that encode green fluorescent protein

Methods and compositions for determining the tumor suppressor status of

Growing community of inventors

San Francisco, CA, United States of America

Ali Fattaey